Green Cross and POSCO Capital leads $13.5 mln round for Juventas Therapeutics

Cleveland-based Juventas Therapeutics, a biotech company that is developing non-viral gene therapies that treat advanced cardiovascular diseases, has raised $13.5 million in Series B-2 funding. Green Cross Holdings and POSCO Capital led the round. Also, Juventas has received $6 million in debt funding from Oxford Finance and may get $9 million more "if specific milestones are met." In addition to the financing, Juventas has named James Boland, Ernst & Young's retired vice chairman, to its board of directors. Boland is also former president and CEO of the Cleveland Cavaliers.

North AmericaUSBriefs